Aviex Technologies LLC was founded
to develop a novel vaccine platform delivery technology for infectious diseases.

The Company

Aviex is a leading-edge biotechnology company that is developing potent vaccines that are administered orally and/or by multi-modality utilizing a novel patented vaccine platform delivery technology.

The Aviex Platform is designed to deliver preventative and therapeutic vaccines for a wide range of human and animal infectious diseases caused by bacterial and parasitic pathogens. The company mission is to develop an ongoing pipeline of vaccine products utilizing the YS1646-based Aviex proprietary platform delivery technology.


Aviex candidate C.difficile AV-0210W will be presented at the Annual Conference for Vaccine Research (ACVR) on April 4th, 2019 in Baltimore, MD.

The first C.difficile manuscript describing the POC research has been accepted by the journal Infection and Immunity for publication in 2019.